ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer.
Saved in:
| Title: | ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer. |
|---|---|
| Authors: | Van Gorp, T.1,2 (AUTHOR) toon.vangorp@uzleuven.be, Cibula, D.3,4 (AUTHOR), Lv, W.5 (AUTHOR), Backes, F.6,7 (AUTHOR), Ortaç, F.8,9 (AUTHOR), Hasegawa, K.10 (AUTHOR), Lindemann, K.11,12,13 (AUTHOR), Savarese, A.14,15 (AUTHOR), Laenen, A.2,16 (AUTHOR), Kim, Y.M.17 (AUTHOR), Bodnar, L.18,19 (AUTHOR), Barretina-Ginesta, M.-P.20,21 (AUTHOR), Gilbert, L.22,23,24 (AUTHOR), Pothuri, B.7,25 (AUTHOR), Chen, X.26,27 (AUTHOR), Flores, M.B.28 (AUTHOR), Levy, T.29 (AUTHOR), Colombo, N.30,31,32 (AUTHOR), Papadimitriou, C.33,34 (AUTHOR), Buchanan, T.7,35 (AUTHOR) |
| Source: | Annals of Oncology. Nov2024, Vol. 35 Issue 11, p968-980. 13p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
